Identification and characterization of new mechanisms in vascular Oestrogen Signalling

Basic and Clinical Pharmacology and Toxicology

Volumn 113, Issue 5, 2013, Pages 287-293

  Holm, Anders ^a   Nilsson, Bengt Olof ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

(3A,4,9B) 4 (6 BROMO 1,3 BENZODIOXOL 5 YL) 3A,4,5,9B 3H CYCLOPENTA[C]QUINOLINE; (3A,4,9B) 4 (6 BROMO 1,3 BENZODIOXOL 5 YL) 3A,4,5,9B TETRAHYDRO 8 (1 METHYLETHYL) 3H CYCLOPENTA[C]QUINOLINE; 1 [(3A,4,9B) 4 (6 BROMO 1,3 BENZODIOXOL 5 YL) 3A,4,5,9B TETRAHYDRO 3H CYCLOPENTA[C]QUINOLIN 8 YL]ETHANONE; 1,3,5 TRIS(4 HYDROXYPHENYL) 4 PROPYLPYRAZOLE; DIARYLPROPIONITRILE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTROGEN; FULVESTRANT; G 1; G 15; G 36; G PROTEIN COUPLED RECEPTOR 30; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; DRUG IDENTIFICATION; DRUG MECHANISM; ENDOTHELIUM CELL; ESTROGEN THERAPY; HEART PROTECTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASCULITIS; VASODILATATION;

ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CELL PROLIFERATION; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; HUMANS; INFLAMMATION; MODELS, ANIMAL; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84885483209     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12118     Document Type: Article

References (51)

1. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-11.
2. Dubey RK, Imthurn B, Barton M, Jackson EK. Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovasc Res 2005;66:295-306.
3. Knowlton AA, Lee AR. Estrogen and the cardiovascular system. Pharmacol Ther 2012;135:54-70.
4. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002;288:321-33.
5. Barton M. Cholesterol and atherosclerosis: modulation by oestrogen. Curr Opin Lipidol 2013;24:214-20.
6. Nofer JR. Estrogens and atherosclerosis: insights from animal models and cell systems. J Mol Endocrinol 2012;48:R13-29.
7. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G et al. Mechanisms of estrogen action. Physiol Rev 2001;81:1535-65.
8. Figtree GA, McDonald D, Watkins H, Channon KM. Truncated estrogen receptor alpha 46-kDa isoform in human endothelial cells: relationship to acute activation of nitric oxide synthase. Circulation 2003;107:120-6.
9. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005;307:1625-30.
10. Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005;146:624-32.
11. Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2006;2:207-12.
12. Dennis MK, Burai R, Ramesh C, Petrie WK, Alcon SN, Nayak TK et al. In vivo effects of a GPR30 antagonist. Nat Chem Biol 2009;5:421-7.
13. Dennis MK, Field AS, Burai R, Ramesh C, Petrie WK, Bologa CG et al. Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity. J Steroid Biochem Mol Biol 2011;127:358-66.
14. Holm A, Baldetorp B, Olde B, Leeb-Lundberg LM, Nilsson BO. The GPER1 agonist G-1 attenuates endothelial cell proliferation by inhibiting DNA synthesis and accumulating cells in the S and G2 phases of the cell cycle. J Vasc Res 2011;48:327-35.
15. Holm A, Grande PO, Luduena RF, Olde B, Prasad V, Leeb-Lundberg LM et al. The G protein-coupled oestrogen receptor 1 agonist G-1 disrupts endothelial cell microtubule structure in a receptor-independent manner. Mol Cell Biochem 2012;366:239-49.
16. Filardo E, Quinn J, Pang Y, Graeber C, Shaw S, Dong J et al. Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. Endocrinology 2007;148:3236-45.
17. Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A et al. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res 2007;67:1859-66.
18. Olde B, Leeb-Lundberg LM. GPR30/GPER1: searching for a role in estrogen physiology. Trends Endocrinol Metab 2009;8:409-16.
19. Otto C, Rohde-Schulz B, Schwarz G, Fuchs I, Klewer M, Brittain D et al. G protein-coupled receptor 30 localizes to the endoplasmic reticulum and is not activated by estradiol. Endocrinology 2008;149:4846-56.
20. Batenburg WW, Jansen PM, van den Bogaerdt AJ, J Danser AH. Angiotensin II-aldosterone interaction in human coronary microarteries involves GPR30, EGFR, and endothelial NO synthase. Cardiovasc Res 2012;94:136-43.
21. Crofton JT, Share L. Gonadal hormones modulate deoxycorticosterone-salt hypertension in male and female rats. Hypertension 1997;29:494-9.
22. Leonardo F, Medeirus C, Rosano GM, Pereira WI, Sheiban I, Gebara O et al. Effect of acute administration of estradiol 17 beta on aortic blood flow in menopausal women. Am J Cardiol 1997;80:791-3.
23. Rubanyi GM, Freay AD, Kauser K, Sukovich D, Burton G, Lubahn DB et al. Vascular estrogen receptors and endothelium-derived nitric oxide production in the mouse aorta. Gender difference and effect of estrogen receptor gene disruption. J Clin Invest 1997;99:2429-37.
24. Pendaries C, Darblade B, Rochaix P, Krust A, Chambon P, Korach KS et al. The AF-1 activation-function of ERalpha may be dispensable to mediate the effect of estradiol on endothelial NO production in mice. Proc Natl Acad Sci U S A 2002;99:2205-10.
25. Cruz MN, Douglas G, Gustafsson JA, Poston L, Kublickiene K. Dilatory responses to estrogenic compounds in small femoral arteries of male and female estrogen receptor-beta knockout mice. Am J Physiol 2006;290:H823-9.
26. Darblade B, Pendaries C, Krust A, Dupont S, Fouque MJ, Rami J et al. Estradiol alters nitric oxide production in the mouse aorta through the alpha-, but not beta-, estrogen receptor. Circ Res 2002;90:413-9.
27. Reslan OM, Yin Z, do Nascimento GR, Khalil RA. Subtype-specific estrogen receptor-mediated vasodilator activity in the cephalic, thoracic azrnd abdominal vasculature of female rat. J Cardiovasc Pharmacol 2013;62:26-40.
28. Traupe T, Stettler CD, Li H, Haas E, Bhattacharya I, Minotti R et al. Distinct roles of estrogen receptors alpha and beta mediating acute vasodilation of epicardial coronary arteries. Hypertension 2007;49:1364-70.
29. Perera M, Petrie JR, Hillier C, Small M, Sattar N, Connell JM et al. Hormone replacement therapy can augment vascular relaxation in post-menopausal women with type 2 diabetes. Hum Reprod 2002;17:497-502.
30. Mikkola T, Turunen P, Avela K, Orpana A, Viinikka L, Ylikorkala O. 17 beta-estradiol stimulates prostacyclin, but not endothelin-1, production in human vascular endothelial cells. J Clin Endocrinol Metab 1995;80:1832-6.
31. Lindsey SH, Cohen JA, Brosnihan KB, Gallagher PE, Chappell MC. Chronic treatment with the Gpr30 agonist G-1 decreases blood pressure in ovariectomized Mren2.Lewis rats. Endocrinology 2009;8:3753-8.
32. Broughton BR, Miller AA, Sobey CG. Endothelium-dependent relaxation by G protein-coupled receptor 30 agonists in rat carotid arteries. Am J Physiol 2010;298:H1055-61.
33. Seok YM, Jang EJ, Reiser O, Hager M, Kim IK. 17beta-Estradiol induces vasorelaxation in a G-protein-coupled receptor 30-independent manner. Naunyn Schmiedebergs Arch Pharmacol 2012;385:945-8.
34. Martensson UE, Salehi SA, Windahl S, Gomez MF, Sward K, Daszkiewicz-Nilsson J et al. Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology 2009;150:687-98.
35. Haas E, Meyer MR, Schurr U, Bhattacharya I, Minotti R, Nguyen HH et al. Differential effects of 17beta-estradiol on function and expression of estrogen receptor alpha, estrogen receptor beta, and GPR30 in arteries and veins of patients with atherosclerosis. Hypertension 2007;49:1358-63.
36. Chakrabarti S, Davidge ST. G-Protein coupled receptor 30 (GPR30): a novel regulator of endothelial inflammation. PLoS One 2012;7:e52357.
37. Haas E, Bhattacharya I, Brailoiu E, Damjanovic M, Brailoiu GC, Gao X et al. Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. Circ Res 2009;3:288-91.
38. Lindsey SH, Carver KA, Prossnitz ER, Chappell MC. Vasodilation in response to the GPR30 agonist G-1 is not different from estradiol in the mRen2.Lewis female rat. J Cardiovasc Pharmacol 2011;57:598-603.
39. Li ZL, Liu JC, Liu SB, Li XQ, Yi DH, Zhao MG. Improvement of vascular function by acute and chronic treatment with the GPR30 agonist G1 in experimental diabetes mellitus. PLoS One 2012;7:e38787.
40. Kitazawa T, Hamada E, Kitazawa K, Gaznabi AK. Non-genomic mechanism of 17 beta-oestradiol-induced inhibition of contraction in mammalian vascular smooth muscle. J Physiol 1997;499(Pt 2):497-511.
41. Holm P, Stender S, Andersen HO, Hansen BF, Nordestgaard BG. Antiatherogenic effect of estrogen abolished by balloon catheter injury in cholesterol-clamped rabbits. Arterioscler Thromb Vasc Biol 1997;17:1504-11.
42. Billon-Gales A, Fontaine C, Douin-Echinard V, Delpy L, Berges H, Calippe B et al. Endothelial estrogen receptor-alpha plays a crucial role in the atheroprotective action of 17beta-estradiol in low-density lipoprotein receptor-deficient mice. Circulation 2009;120:2567-76.
43. Delarue F, Daunes S, Elhage R, Garcia A, Bayard F, Faye J. Estrogens modulate bovine vascular endothelial cell permeability and HSP 25 expression concomitantly. Am J Physiol 1998;275:H1011-5.
44. Gao H, Liang M, Bergdahl A, Hamren A, Lindholm MW, Dahlman-Wright K et al. Estrogen attenuates vascular expression of inflammation associated genes and adhesion of monocytes to endothelial cells. Inflamm Res 2006;55:349-53.
45. Weil BR, Manukyan MC, Herrmann JL, Wang Y, Abarbanell AM, Poynter JA et al. Signaling via GPR30 protects the myocardium from ischemia/reperfusion injury. Surgery 2010;148:436-43.
46. Arnal JF, Douin-Echinard V, Brouchet L, Tremollieres F, Laurell H, Lenfant F et al. Understanding the oestrogen action in experimental and clinical atherosclerosis. Fundam Clin Pharmacol 2006;20:539-48.
47. Pare G, Krust A, Karas RH, Dupont S, Aronovitz M, Chambon P et al. Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res 2002;90:1087-92.
48. Filipe C, Lam Shang Leen L, Brouchet L, Billon A, Benouaich V, Fontaine V et al. Estradiol accelerates endothelial healing through the retrograde commitment of uninjured endothelium. Am J Physiol 2008;294:H2822-30.
49. Toutain CE, Filipe C, Billon A, Fontaine C, Brouchet L, Guery JC et al. Estrogen receptor alpha expression in both endothelium and hematopoietic cells is required for the accelerative effect of estradiol on reendothelialization. Arterioscler Thromb Vasc Biol 2009;29:1543-50.
50. Gros R, Ding Q, Liu B, Chorazyczewski J, Feldman RD. Aldosterone mediates its rapid effects in vascular endothelial cells through GPER/GPR30 activation. Am J Physiol 2013;304:C532-40.
51. Ding Q, Gros R, Limbird LE, Chorazyczewski J, Feldman RD. Estradiol-mediated ERK phosphorylation and apoptosis in vascular smooth muscle cells requires GPR 30. Am J Physiol 2009;297:C1178-87.